AUA Annual Meeting to Feature New Outcomes Research from Analysis Group
Event:AUA2025
Dates:
April 26–29, 2025
Host:
American Urological Association
Location:
Las Vegas, NV
Research coauthored by consultants from Analysis Group’s HEOR, Epidemiology & Market Access practice will be presented at the American Urological Association’s (AUA’s) annual meeting, which will be held April 26-29, 2025, in Las Vegas, NV.
The firm’s research will be featured in one podium presentation and three poster presentations.
Podium Presentation:
- “Real-world time-to-next-treatment and time-to-castration-resistance among patients with metastatic castration-sensitive prostate cancer using androgen-receptor pathway inhibitors with and without homologous recombination repair alterations,” coauthored by an Analysis Group team – including Vice President Dominic Pilon, Manager Carmine Rossi, Senior Research Professional Lilian Diaz, and Research Professional Yuxi Wang – in collaboration with researchers from Emory University School of Medicine, Fred Hutch Cancer Center, New Jersey Urology, Carolina Urologic Research Center, Chesapeake Urology, and Johnson & Johnson Innovative Medicine (sponsor).
Poster Presentations:
- “Healthcare burden associated with cystectomy and trimodal therapy among patients with muscle invasive bladder cancer in the United States,” coauthored by an Analysis Group team – including Vice Presidents Dominic Pilon and Bruno Émond, Manager Carmine Rossi, and Senior Research Professional Anabelle Tardif-Samson – in collaboration with researchers from the University of Texas MD Anderson Cancer Center and Johnson & Johnson Innovative Medicine (sponsor).
- “Homologous recombination repair alterations, next-generation sequencing testing, and time-to-next-treatment by race among patients with metastatic castration-sensitive prostate cancer,” coauthored by an Analysis Group team – including Vice President Dominic Pilon, Manager Carmine Rossi, Senior Research Professional Lilian Diaz, and Research Professionals Yuxi Wang and Gordon Wong – in collaboration with researchers from Emory University School of Medicine, Fred Hutch Cancer Center, New Jersey Urology, Carolina Urologic Research Center, Chesapeake Urology, and Johnson & Johnson Innovative Medicine (sponsor).
- “Real-world comparison of prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer treated with apalutamide or enzalutamide,” coauthored by an Analysis Group team – including Vice President Dominic Pilon, Manager Carmine Rossi, Associate Frederic Kinkead, and Senior Research Professional Lilian Diaz – in collaboration with researchers from Chesapeake Urology, New Jersey Urology, and Johnson & Johnson Innovative Medicine (sponsor).